-+ 0.00%
-+ 0.00%
-+ 0.00%

MAIA Biotechnology Doses First Patient In Taiwan In Expansion Phase Of THIO-101 Phase 2 Trial For Advanced Non-Small Cell Lung Cancer

Benzinga·07/09/2025 13:16:16
Listen to the news

MAIA Biotechnology, Inc. (NYSE:MAIA), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced dosing of the first patient in Taiwan in the expansion phase of its THIO-101 Phase 2 trial for advanced non-small cell lung cancer (NSCLC). The trial's entry into another continent marks a key milestone for MAIA, opening a significantly larger patient pool for its evaluations of ateganosine (THIO). Screening for the trial is ongoing in Europe and Asia.